Led · Series C · May 2025

Rad AI develops generative AI products for radiology, including Rad AI Impressions, Rad AI Reporting, and Rad AI Continuity, that are embedded into radiologists' workflows. Its Impressions product automates the impression section and saves radiologists more than an hour per shift on average. Rad AI Reporting includes features such as Omni Unchanged and Omni Report, which cut follow-up dictation time by 50%, reduce spoken words by 90%, and can double reporting speed. Rad AI Continuity automates tracking and coordination of incidental findings and has improved follow-up exam completion rates from approximately 30% to over 75% at users. The platform is trusted by thousands of U.S. radiologists and supports providers responsible for nearly half of all imaging volume in the U.S. The company is scaling enterprise deployments across hospitals and clinics with health-system partners to expand adoption and improve care coordination and efficiency. Rad AI develops generative AI solutions for radiology including Rad AI Impressions, Rad AI Reporting, and Rad AI Continuity that automate draft report text, reduce dictated words, and close the loop on actionable findings. Its flagship Rad AI Reporting can reduce dictated words by up to 90% and save providers up to 50% of their time; Rad AI Continuity has raised follow-up rates at health systems from about 30% to 75% or more. The company's products are used by thousands of U.S. radiologists daily and are deployed at health systems and practices that account for nearly 50% of U.S. medical imaging. Rad AI says it was the first to commercialize a generative AI product in healthcare and has been recognized by CB Insights and AuntMinnie for its products. The company is hiring across roles and plans to accelerate development and deployment of its generative AI technology to healthcare providers and systems globally. Rad AI builds software that generates radiology reports, aiming to cut the time radiologists spend on documentation. The company developed a proprietary LLM trained on radiology report datasets to automate findings and impressions. Rad AI says it began using LLMs in 2018 and positions itself as an early adopter of generative AI in radiology. Its products are used by about a third of U.S. health systems and nine of the 10 largest radiology groups. The company has raised over $80 million in total capital after a $50M Series B and plans to use the fresh funding to build a team to deploy a standalone radiology reporting solution. Rad AI is hiring staff to install and maintain the software and reports it has not lost a single customer since launch. Rad AI provides an AI platform that automatically generates customized impressions from dictated findings and clinical indications, learning each radiologist’s language preferences from prior reports. Its core offerings, Rad AI Omni and Rad AI Continuity, aim to improve report accuracy and consistency, surface significant incidental findings, and provide guideline-based follow-up recommendations. Omni injects the impression directly into the practice’s voice recognition software without extra clicks or windows, while Continuity closes the loop on follow-up by integrating into health systems’ EMRs and offering an outpatient platform. The company emphasizes time savings for radiologists, improved report processes, and reduced burnout. Rad AI is working with seven of the ten largest private radiology practices in the U.S. and plans to use new funding to further develop and commercialize its products. Rad AI, founded in 2018 by Doktor Gurson and Dr. Jeff Chang in Berkeley, Calif., builds machine-learning tools to automate repetitive radiology tasks. Its first product automatically generates the impression section of radiology reports, customized to each radiologist's preferred language. The company raised $4M in seed funding to build out its engineering team and expand the rollout of its first product to more radiology groups and customers. The round was led by Gradient Ventures, with participation from UP2398, Precursor Ventures, GMO Venture Partners, Array Ventures, Hike Ventures, Fifty Years VC and various angels. Current partners include Greensboro Radiology, Medford Radiology, Einstein Healthcare Network and Bay Imaging Consultants, along with other radiology groups yet to be announced.

Participated · Equity · Oct 2023

Capital Rx operates a cloud-native pharmacy benefit management (PBM) platform that adjudicates prescription drug claims and provides price transparency to employers, insurers, and other payers. The company is now broadening its technology to handle medical claims as well, positioning itself as an end-to-end claims processor across both pharmacy and medical benefits. By unifying these workflows, Capital Rx aims to give payers better visibility into total healthcare spending and negotiate more favorable rates. Management says the fresh capital will accelerate product expansion and support additional hiring to meet customer demand. The firm reports an oversubscribed funding round and cites strong interest from new and existing investors. A spokesperson disclosed that Capital Rx now carries a $3.25 billion valuation, underscoring investor confidence in its growth trajectory. Although detailed revenue or user metrics were not provided, the company emphasized that the additional funds will enable it to scale its platform nationwide.

Participated · Series B · Dec 2021

Babyscripts offers a mobile clinical solution for remote monitoring in pregnancy, combining a mobile app with internet-connected devices, digital education, and customized risk-specific experiences. The platform enables providers and payers to manage patients via risk-based care modules, remote monitoring, and automated care elements. Babyscripts reports managing more than 200K unique pregnancies across 30 states and says its tools can allow providers to manage up to 90% of pregnancies virtually. The solution is delivered via a joint deployment model that incorporates payers sponsoring platform use at participating sites to identify and triage member risk and improve care coordination. The company emphasizes targeting and reducing systemic racial and ethnic inequities in maternal and infant outcomes. Babyscripts intends to use the new funding to accelerate rollout of its Virtual Maternity Care solution across U.S. providers and to develop models specifically designed for payers; the company has raised $37M to date. Babyscripts offers a virtual maternity care platform that pairs medical-device kits (blood pressure, weight, captured blood sugars) with a mobile app to monitor and alert clinicians to maternal health issues. The platform can automate roughly 40%–50% of prenatal care and has been shown to accelerate diagnoses (for example, preeclampsia detected 13 days faster than standard care at a site). Babyscripts is used by 75 health systems across 32 states and monitors about 250,000 women annually; more than 70% of its patients are on Medicaid. The company expanded product lines from a single device to multiple targeted kits and recently launched a mental health product while developing a substance use disorder experience. Babyscripts has formed partnerships with public health departments, managed Medicaid plans and providers to enable local payment and broader deployment. The company grew enrollments 10x during the pandemic and has 45 employees, with plans to double headcount in the next 12–18 months to support product, payer growth, clinical expertise, implementation and customer success. Babyscripts builds a clinically validated virtual care platform that allows OBGYNs to deliver a new model of prenatal and postpartum care using internet-connected devices for remote monitoring. The platform offers risk-specific experiences and the company says it can allow providers to manage up to 90% of pregnancies virtually. Babyscripts has spent six years developing what it describes as the most-implemented mobile clinical solution for remote monitoring in pregnancy and was named to CB Insights' 2020 Digital Health 150. The company emphasizes partnering with physicians and health systems to guide product development and improve maternal outcomes. Its stated mission is to eliminate maternal mortality and expand access to care. Recent health-system partnerships are intended to align Babyscripts' roadmap with customer needs and support scaling of its virtual maternity care solutions. Babyscripts offers a clinically-validated virtual care obstetrics platform that uses internet-connected devices for remote monitoring to support prenatal and postpartum care. The core product delivers risk-specific experiences to allow OBGYNs to manage a large portion of pregnancies remotely. The system is designed to detect risk more quickly and automate elements of care, enabling providers to manage up to 90% of pregnancies virtually. Led by CEO and co-founder Anish Sebastian, the company has spent the last four years building this platform. Babyscripts recently acquired iBirth, expanding its offering to include a provider-delivered, co-branded pregnancy app and a more holistic pregnancy and postpartum program. Financially, Babyscripts raised $500K from Inova Health System, which will support deployment of the platform. Babyscripts develops a mobile app and remote-monitoring devices that track blood pressure and weight and deliver neonatal care information to expecting mothers. The company works with hospitals and healthcare providers to distribute its devices and software, creating a channel between patients and OBGYNs throughout pregnancy. Using remote monitoring, Babyscripts says it can tailor treatments to risk profiles and enable providers to manage up to 90% of pregnancies virtually. The platform is already being used to monitor 160,000 pregnancies across 20 states, and the company reports average patient engagement of six app or monitoring interactions per week. Leadership says the company will use funding to continue acquiring market share and build additional products for pregnancy patients, including postpartum and early-stage pediatric services through expanded offerings.